Global Leader in DNA Sequencing Illumina (ILMN) Bests the Streets 2Q Estimates & Shares Shoot Up +13%
Illumina (NasdaqGM: ILMN) reported earnings today and bested the streets’ estimates. Illumina reported revenue of $662 million, a 10% increase compared to $600 million in the second quarter of 2016. GAAP net income attributable to Illumina stockholders was reported for the quarter of $128 million, or $0.87 per diluted share, compared to $120 million, or $0.82 per diluted share, for the second quarter of 2016. The Company has raised its full-year revenue forecast on higher-than-expected demand for Illumina’s new gene-sequencing technology.
Ilumina is improving human health by unlocking the power of the genome. Thier focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com.